The SIOPEN BIOPORTAL is a prospective non-therapeutic multi-centre international study aimed at developing an international Registry linked to a Virtual Biobank for all the patients with peripheral neuroblastic tumor within countries of the SIOPEN network. The overall aim of this study is to provide a GDPR-compliant framework to collect basic clinical annotations, biological and genetic features and information about the location on biospecimens for all the patients with a peripheral neuroblastic tumor including neuroblastoma, ganglioneuroblastoma and ganglioneuroma in the SIOPEN network. This study will support data and sample management and intensify cross-borders data and sample sharing fostering translational and clinical research. The post-hoc hypothesis formulated based on the data generated in this study will be used as statistical basis for future precision medicine programs based on improved biological characterization, patient stratification and therapeutic management.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
600
Additional blood sampling (not mandatory)
Fakultni nemocnice v Motole
Prague, Czechia
RECRUITINGCHU Amiens
Amiens, France
RECRUITINGChu Angers
Angers, France
RECRUITINGHôpital Jean Minjoz
Besançon, France
Rate of patients having their clinical data registered
Registry Outcome: Rate of patients having their clinical data registered throughout their treatment and follow-up from the total of patients registered
Time frame: 6 months
Rate of patients for whom information on biological samples/material is collected
Virtual Biobank Outcome: Rate of patients for whom information on biological samples/material collected and stored in SIOPEN is available from the total of patients registered
Time frame: 6 months
Progression-free survival (PFS)
Investigation of the impact of the variables currently used for assignment to risk groups and treatment stratification (MYCN Status, ALK Status, stage, age, primary tumor site) on progression-free survival (PFS) using the Kaplan-Meier method
Time frame: 12 months
Overall-survival (OS)
Investigation of the impact of the variables currently used for assignment to risk groups and treatment stratification (MYCN Status, ALK Status, stage, age, primary tumor site) on overall-survival (OS) using the Kaplan-Meier method
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hôpital des enfants
Bordeaux, France
RECRUITINGChru Brest
Brest, France
RECRUITINGCHU CAEN - Fédération de cancérologie - niveau 21
Caen, France
RECRUITINGCHU D'Estaing de CLERMONT FERRAND
Clermont-Ferrand, France
RECRUITINGDIJON Hôpital d'enfants
Dijon, France
RECRUITINGChu Grenoble
Grenoble, France
RECRUITING...and 28 more locations